<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Supreme Pharmaceuticals Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/PjxA3nMdEwV79n4b6OV0cg==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2017, Supreme Pharmaceuticals Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Wed, 20 Sep 2017 12:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/09/20/1125202/0/en/Supreme-Completes-Sale-with-Emerald-Health-Botanicals-Inc.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/09/20/1125202/0/en/Supreme-Completes-Sale-with-Emerald-Health-Botanicals-Inc.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:FIRE</category>
      <title>Supreme Completes Sale with Emerald Health Botanicals Inc.</title>
      <description><![CDATA[<p align="left">TORONTO, Sept.  20, 2017  (GLOBE NEWSWIRE) -- Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (TSXV:FIRE) is pleased to announce its wholly owned subsidiary, 7ACRES, has completed a sale of dried cannabis to Emerald Health Botanicals Inc. (“<strong>Emerald</strong>”), a wholly owned subsidiary of Emerald Health Therapeutics, Inc. (TSXV:EMH).   Emerald is a Canadian Licensed Producer with a focus on advancing the science of medical cannabis through a deep commitment to research.  All cannabis procured from 7ACRES by Emerald will be re-sold with a producer’s mark specifying the cannabis as “<strong>SunGrown by 7ACRES</strong>”.</p>]]></description>
      <pubDate>Wed, 20 Sep 2017 12:00 GMT</pubDate>
      <dc:identifier>1125202</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 12:02 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/09/05/1107589/0/en/Supreme-Completes-First-Sales-with-Aurora-Cannabis.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/09/05/1107589/0/en/Supreme-Completes-First-Sales-with-Aurora-Cannabis.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:FIRE</category>
      <title>Supreme Completes First Sales with Aurora Cannabis</title>
      <description><![CDATA[<p align="justify">TORONTO, Sept.  05, 2017  (GLOBE NEWSWIRE) -- Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (TSXV:FIRE) is pleased to announce its wholly owned subsidiary, 7ACRES, has completed its first sale of dried cannabis to Aurora Cannabis Inc. (“<strong>Aurora</strong>”), one of Canada’s leading Licensed Producers. Aurora will sell cannabis procured from 7ACRES to its medical cannabis patients with a producer’s mark specifying the cannabis as “<strong>SunGrown by 7ACRES</strong>”.<br></p>]]></description>
      <pubDate>Tue, 05 Sep 2017 11:16 GMT</pubDate>
      <dc:identifier>1107589</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Tue, 05 Sep 2017 11:16 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/28/1092161/0/en/Supreme-Receives-Sales-Approval.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/28/1092161/0/en/Supreme-Receives-Sales-Approval.html</link>
      <title>Supreme Receives Sales Approval</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - June 28, 2017) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (TSX VENTURE:FIRE) is pleased to announce that its wholly-owned operating subsidiary, 7ACRES, has been granted its permission to sell under the <em>Access to Cannabis for Medical Purposes Regulations</em>. </p>]]></description>
      <pubDate>Wed, 28 Jun 2017 19:00 GMT</pubDate>
      <dc:identifier>1092161</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/01/1092159/0/en/Supreme-Announces-Listing-of-Common-Shares-on-the-TSX-V-under-the-symbol-FIRE.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/01/1092159/0/en/Supreme-Announces-Listing-of-Common-Shares-on-the-TSX-V-under-the-symbol-FIRE.html</link>
      <title>Supreme Announces Listing of Common Shares on the TSX.V under the symbol "FIRE"</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - June 1, 2017) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (CSE:SL)(CSE:SL.CN)(CNSX:SL)(OTC PINK:SPRWF) is pleased to announce that it has received final approval from the TSX Venture Exchange ("<strong>TSX.V</strong>") to list the Company's common shares on the TSX.V. The common shares are expected to begin trading on the TSX.V at the opening of markets on June 6, 2017 under the symbol "FIRE". In connection with listing on the TSX.V, Supreme's common shares will be voluntarily delisted from the Canadian Securities Exchange at the close of markets on June 5, 2017.</p>]]></description>
      <pubDate>Thu, 01 Jun 2017 21:06 GMT</pubDate>
      <dc:identifier>1092159</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/08/1092158/0/en/Supreme-Updates-Board-of-Directors-and-Provides-Licensing-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/05/08/1092158/0/en/Supreme-Updates-Board-of-Directors-and-Provides-Licensing-Update.html</link>
      <title>Supreme Updates Board of Directors and Provides Licensing Update</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - May 8, 2017) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (CSE:SL)(CSE:SL.CN)(CNSX:SL) is pleased to announce that Mr. Ron Factor, B.A.Sc, MBA, has joined its Board of Directors. Mr. Factor was the founder of the global supply chain management consulting practice at Deloitte Consulting in Toronto. He will replace Mr. Chuck Rifici on the Board, who has resigned to focus his efforts on a new venture. The Supreme Board of Directors thanks Mr. Rifici for his contributions to the Company. </p>]]></description>
      <pubDate>Mon, 08 May 2017 11:00 GMT</pubDate>
      <dc:identifier>1092158</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/10/1092156/0/en/Supreme-Announces-Conditional-Approval-to-List-on-the-TSX-V.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/04/10/1092156/0/en/Supreme-Announces-Conditional-Approval-to-List-on-the-TSX-V.html</link>
      <title>Supreme Announces Conditional Approval to List on the TSX.V</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - April 10, 2017) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (CSE:SL)(CSE:SL.CN) is pleased to announce that it has received conditional approval from the TSX Venture Exchange ("<strong>TSX.V</strong>") to list the Company's common shares on the TSX.V.</p>]]></description>
      <pubDate>Mon, 10 Apr 2017 13:44 GMT</pubDate>
      <dc:identifier>1092156</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/11/1092154/0/en/Supreme-Announces-License-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/03/11/1092154/0/en/Supreme-Announces-License-Update.html</link>
      <title>Supreme Announces License Update</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - March 10, 2017) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (CSE:SL)(CSE:SL.CN) announces that its wholly-owned subsidiary 7 ACRES has received a renewal of its license to cultivate cannabis pursuant to the <em>Access to Cannabis for Medical Purposes Regulations </em>("<strong>ACMPR</strong>"). Supreme also understands that Health Canada is in the final phase of its review of 7 ACRES' application (the "<strong>Application</strong>") for the authorization to sell bulk cannabis. The Application was submitted in November 2016 followed by a site inspection in January 2017.</p>]]></description>
      <pubDate>Sat, 11 Mar 2017 02:51 GMT</pubDate>
      <dc:identifier>1092154</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/12/17/1092152/0/en/Supreme-Announces-Voting-Results-for-the-Annual-General-Meeting-of-Shareholders.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/12/17/1092152/0/en/Supreme-Announces-Voting-Results-for-the-Annual-General-Meeting-of-Shareholders.html</link>
      <title>Supreme Announces Voting Results for the Annual General Meeting of Shareholders</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - Dec. 16, 2016) -</strong> Supreme Pharmaceuticals Inc. ("<strong>Supreme</strong>" or the "<strong>Company</strong>") (CSE:SL)(CSE:SL.CN) announces that at the annual general meeting of its shareholders (the "<strong>Meeting</strong>") held in Toronto, Ontario on December 16, 2016, the shareholders approved the election of Mr. Chuck Rifici as a director of the Company. Mr. Rifici joins current directors Mr. Michael La Brier, Mr. Scott Walters, Mr. Navdeep Dhaliwal and Mr. John Fowler who were re-elected as directors at the Meeting. At the Meeting, the shareholders also approved the re-appointment of MNP LLP as auditors of the Company for the ensuing year. </p>]]></description>
      <pubDate>Sat, 17 Dec 2016 00:05 GMT</pubDate>
      <dc:identifier>1092152</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/17/1092149/0/en/Supreme-Pharmaceuticals-Announces-Additional-5-Million-Non-Brokered-Private-Placement-of-Convertible-Debenture-Units.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/11/17/1092149/0/en/Supreme-Pharmaceuticals-Announces-Additional-5-Million-Non-Brokered-Private-Placement-of-Convertible-Debenture-Units.html</link>
      <title>Supreme Pharmaceuticals Announces Additional, $5 Million Non-Brokered Private Placement of Convertible Debenture Units</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - Nov. 17, 2016) -</strong> </p>]]></description>
      <pubDate>Thu, 17 Nov 2016 23:45 GMT</pubDate>
      <dc:identifier>1092149</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/10/27/1092147/0/en/Supreme-Provides-Clarification-Regarding-Health-Canada-Website.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/10/27/1092147/0/en/Supreme-Provides-Clarification-Regarding-Health-Canada-Website.html</link>
      <title>Supreme Provides Clarification Regarding Health Canada Website</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - Oct. 27, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(CSE:SL.CN)(OTC PINK:SPRWF) </strong>wishes to clarify that, as a result of changes Health Canada made to its website today, Supreme's operating subsidiary, AMMCan, was mistakenly shown as having been approved for the sale of dried marihuana. Supreme notified IIROC upon learning of this inadvertent change to Health Canada's website, and the common shares were halted from trading. The Health Canada website has since been corrected. Supreme wishes to clarify that, at this time, AMMCan has not yet been approved by Health Canada to sell dried marihuana but continues to take steps towards gaining such approval. Today's events have no impact on AMMCan's status as a Licensed Producer and are unrelated to AMMCan's progress towards obtaining the sales approval. Further updates relating to the status of AMMCan's licensing will be provided as they become available. Supreme's common shares are expected to resume trading following shortly dissemination of this news release.</p>]]></description>
      <pubDate>Thu, 27 Oct 2016 20:19 GMT</pubDate>
      <dc:identifier>1092147</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/14/1092145/0/en/Supreme-Issues-Incentive-Stock-Options.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/09/14/1092145/0/en/Supreme-Issues-Incentive-Stock-Options.html</link>
      <title>Supreme Issues Incentive Stock Options</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - Sept. 14, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF)</strong> has issued 130,000 stock options (each an "<strong>Option</strong>") to a consultant of the Company. Each Option has an exercise price of $0.77 and is exercisable at any time prior to September 14<sup>th</sup>, 2021, subject to the terms and conditions of the Company's Employee Stock Option Plan.</p>]]></description>
      <pubDate>Wed, 14 Sep 2016 12:48 GMT</pubDate>
      <dc:identifier>1092145</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/30/1092144/0/en/Supreme-Closes-Private-Placement-for-Aggregate-Proceeds-of-14-949-755.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/08/30/1092144/0/en/Supreme-Closes-Private-Placement-for-Aggregate-Proceeds-of-14-949-755.html</link>
      <title>Supreme Closes Private Placement for Aggregate Proceeds of $14,949,755</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - Aug. 30, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF) </strong>is pleased to announce it has closed the third tranche of its previously announced non-brokered private placement (the "<strong>Financing</strong>") for proceeds of $10,610,625 and aggregate proceeds from three tranches of $14,949,755. Pursuant to the Financing, the Company issued an aggregate 37,374,388 units (each a "<strong>Unit</strong>") at a price of $0.40 per Unit. Each Unit consists of one common share ("<strong>Common Share</strong>") and one Common Share purchase warrant ("<strong>Warrant</strong>"). Each warrant is exercisable for one Common Share of the corporation at a price of $0.50 for a period of three years from closing. The Company will use net proceeds of the Financing for the expansion of the Company's Hybrid Greenhouse facility and for general working capital purposes.</p>]]></description>
      <pubDate>Tue, 30 Aug 2016 13:28 GMT</pubDate>
      <dc:identifier>1092144</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/08/1092142/0/en/Supreme-Closes-4-Million-Mortgage.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/08/08/1092142/0/en/Supreme-Closes-4-Million-Mortgage.html</link>
      <title>Supreme Closes $4 Million Mortgage</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - Aug. 8, 2016) -</strong> Supreme Pharmaceuticals Inc. (the "Company") (CSE:SL)(OTC PINK:SPRWF) is pleased to announce that it has closed a $4,000,000 mortgage (the "<strong>Mortgage</strong>") with a private lender with respect of its wholly owned subsidiary, 8528934 Canada Ltd. ("<strong>7 ACRES</strong>") and the 7 ACRES' Hybrid Greenhouse in Kincardine, Ontario. The Mortgage is a one-year, 12%, fixed-rate, interest only facility. The proceeds from the Mortgage were used to re-finance the prior vendor-take back mortgage.</p>]]></description>
      <pubDate>Mon, 08 Aug 2016 12:00 GMT</pubDate>
      <dc:identifier>1092142</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/15/1092140/0/en/Supreme-Closes-Second-Tranche-of-Private-Placement-for-Aggregate-Proceeds-of-4-34m-and-Secures-Additional-Long-Term-Supply-Agreement.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/07/15/1092140/0/en/Supreme-Closes-Second-Tranche-of-Private-Placement-for-Aggregate-Proceeds-of-4-34m-and-Secures-Additional-Long-Term-Supply-Agreement.html</link>
      <title>Supreme Closes Second Tranche of Private Placement for Aggregate Proceeds of $4.34m and Secures Additional Long Term Supply Agreement</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - July 15, 2016) -</strong> <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF) </strong>is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement (the "<strong>Financing</strong>") for proceeds of $723,250 and aggregate proceeds from both tranches of $4,339,130. Upon closing, the company issued 1,808,125 units (each a "<strong>Unit</strong>") at a price of $0.40 per Unit. Each Unit consists of one common share ("<strong>Common Share</strong>") and one Common Share purchase warrant ("<strong>Warrant</strong>"). Each warrant is exercisable for one Common Share of the corporation at a price of $0.50 for a period of three years from closing.</p>]]></description>
      <pubDate>Fri, 15 Jul 2016 12:00 GMT</pubDate>
      <dc:identifier>1092140</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/22/1092138/0/en/Supreme-Completes-First-B2B-Genetics-Sale.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/22/1092138/0/en/Supreme-Completes-First-B2B-Genetics-Sale.html</link>
      <title>Supreme Completes First B2B Genetics Sale</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - June 22, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF) </strong>via its wholly owned subsidiary is pleased to announce it has completed its first sale of cannabis genetics to another Canadian Licensed Producer (the "LP"). Pursuant to the transaction, Supreme provided the LP with 6 strains for production and future sale to the LP's registered clients. The sale represents Supreme's first MMPR revenue.</p>]]></description>
      <pubDate>Wed, 22 Jun 2016 23:53 GMT</pubDate>
      <dc:identifier>1092138</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/20/1092136/0/en/Supreme-Closes-3-6-Million-Private-Placement.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/20/1092136/0/en/Supreme-Closes-3-6-Million-Private-Placement.html</link>
      <title>Supreme Closes $3.6 Million Private Placement</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - June 20, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company") (OTC PINK:SPRWF) (CSE:SL)</strong> is pleased to announce that it has closed the first tranche of a non-brokered private placement (the "<strong>Financing</strong>") for gross proceeds of $3,615,880 Upon closing, the Company issued 9,039,700 units (each a "<strong>Unit</strong>") at a price of $0.40 per Unit. Each Unit consists of one common share ("<strong>Common Share</strong>") and one Common Share purchase warrant ("<strong>Warrant</strong>"). Each Warrant is exercisable for one Common Share at a price of $0.50 for a period of three years from closing.</p>]]></description>
      <pubDate>Mon, 20 Jun 2016 23:41 GMT</pubDate>
      <dc:identifier>1092136</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/06/1092134/0/en/Supreme-Expands-B2B-Business-Through-Genetics-Agreement.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/06/1092134/0/en/Supreme-Expands-B2B-Business-Through-Genetics-Agreement.html</link>
      <title>Supreme Expands B2B Business Through Genetics Agreement</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - June 6, 2016) -</strong> <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF</strong><strong>) </strong>via its wholly owned subsidiary has entered into a letter of intent with a Canadian Licensed Producer (a "LP") with respect to the long-term supply by the Company of multiple premium cannabis cultivars for production by the LP. The transaction is conditional upon the parties obtaining applicable regulatory approvals, execution of definitive agreements, and other customary closing conditions. Supreme anticipates the transaction to close within the next sixty (60) days.
        </p>]]></description>
      <pubDate>Mon, 06 Jun 2016 12:00 GMT</pubDate>
      <dc:identifier>1092134</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/20/1092132/0/en/Supreme-Secures-Multiple-Long-Term-Supply-Agreements.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/05/20/1092132/0/en/Supreme-Secures-Multiple-Long-Term-Supply-Agreements.html</link>
      <title>Supreme Secures Multiple Long Term Supply Agreements</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - May 20, 2016) -</strong> <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF) </strong>is pleased to announce that its wholly owned subsidiary AMMCan has entered into Letters of Intent ("LOIs") with respect to the long-term supply of dried cannabis to five (5) Licensed Producers (as such term is defined in the <em>Marihuana for Medical Purposes Regulations</em>). These transactions are conditional upon the parties obtaining applicable regulatory approvals, including AMMCan obtaining a sales license under the MMPR, execution of definitive agreements, completion of satisfactory due diligence, and other customary closing conditions. Upon the execution and delivery of definitive agreements, such agreements would allocate for sale more than 250 kg of dried marijuana and 70 kg of dried marijuana trim in 2016, representing substantially all of AMMCan's anticipated 2016 production. The agreements will be renewable for successive one year periods unless otherwise terminated in accordance with their terms.</p>]]></description>
      <pubDate>Fri, 20 May 2016 12:00 GMT</pubDate>
      <dc:identifier>1092132</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/25/1092130/0/en/Supreme-Strengthens-Board-of-Directors.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/04/25/1092130/0/en/Supreme-Strengthens-Board-of-Directors.html</link>
      <title>Supreme Strengthens Board of Directors</title>
      <description><![CDATA[<p style="&#xA;            text-align:left;&#xA;          ">TORONTO, ONTARIO--(Marketwired - April 25, 2016) - <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL)(OTC PINK:SPRWF) </strong>is pleased to announce the strengthening of its Board of Directors, following receipt of the federal license to cultivate marijuana at its 7 acre (342,000 sq. ft.) hybrid greenhouse facility in Kincardine, Ontario.</p>]]></description>
      <pubDate>Mon, 25 Apr 2016 12:00 GMT</pubDate>
      <dc:identifier>1092130</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/05/1092128/0/en/Supreme-Establishes-Strategic-Alliance-With-Dinafem-Seeds.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/04/05/1092128/0/en/Supreme-Establishes-Strategic-Alliance-With-Dinafem-Seeds.html</link>
      <title>Supreme Establishes Strategic Alliance With Dinafem Seeds</title>
      <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - April 5, 2016) -</strong> <strong>Supreme Pharmaceuticals Inc. (the "Company" or "Supreme") (CSE:SL) (OTC PINK:SPRWF)</strong> is pleased to announce it has established a strategic alliance (the "Strategic Alliance") with top international cannabis seed developer Dinafem Seeds ("Dinafem") based in San Sebastian, Spain. Since 2002, Dinafem has been a global leader in the innovation and standardization of cannabis genetics including pioneering many feminized and auto-flowering varieties. </p>]]></description>
      <pubDate>Tue, 05 Apr 2016 12:00 GMT</pubDate>
      <dc:identifier>1092128</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Supreme Pharmaceuticals Inc.</dc:contributor>
      <dc:modified>Fri, 08 Sep 2017 20:12 GMT</dc:modified>
    </item>
  </channel>
</rss>